TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase II Randomised, Double Blind, Multicentre Study to Assess the Efficacy of AZD2281 in the Treatment of Patients With Platinum Sensitive Relapsed Serous Ovarian Cancer Following Treatment With Two or More Platinum Containing Regimens
Brief Summary: The primary purpose of this study to determine if AZD2281 is effective and well tolerated in maintaining the improvement in your cancer after previous platinum-based chemotherapy


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: olaparib, Drug: paclitaxel, Drug: Drug: carboplatin | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: paclitaxel, Drug: carboplatin | Intervention Type: DRUG; Name: olaparib; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: paclitaxel; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: carboplatin; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: paclitaxel; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Drug: carboplatin; Assigned to Arm(s): 1
B: Arm Label: Olaparib; Type: EXPERIMENTAL; Interventions: Drug: Olaparib | Arm Label: Chemotherapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: carboplatin + gemcitabine or carboplatin + paclitaxel or carboplatin + liposomal doxorubicin or liposomal doxorubicin 4-weekly or topotecan or paclitaxel weekly | Intervention Type: DRUG; Name: Olaparib; Assigned to Arm(s): Olaparib | Intervention Type: DRUG; Name: carboplatin + gemcitabine or carboplatin + paclitaxel or carboplatin + liposomal doxorubicin or liposomal doxorubicin 4-weekly or topotecan or paclitaxel weekly; Assigned to Arm(s): Chemotherapy
C: Arm Label: Olaparib tablets p.o. 300mg twice daily; Type: EXPERIMENTAL; Interventions: Drug: Olaparib 300mg tablets | Arm Label: Placebo tablets p.o. twice daily; Type: PLACEBO_COMPARATOR; Interventions: Drug: Olaparib 300mg tablets | Intervention Type: DRUG; Name: Olaparib 300mg tablets; Assigned to Arm(s): Olaparib tablets p.o. 300mg twice daily, Placebo tablets p.o. twice daily
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: AZD2281 | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: matching placebo | Intervention Type: DRUG; Name: AZD2281; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: matching placebo; Assigned to Arm(s): 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase II Randomised, Double Blind, Multicentre Study to Assess the Efficacy of AZD2281 in the Treatment of Patients With Platinum Sensitive Relapsed Serous Ovarian Cancer Following Treatment With Two or More Platinum Containing Regimens
Brief Summary: The primary purpose of this study to determine if AZD2281 is effective and well tolerated in maintaining the improvement in your cancer after previous platinum-based chemotherapy


Options:
A: Arm Label: Arm A: Chemotherapy + Bevacizumab + Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Bevacizumab, Drug: Chemotherapy, Drug: Placebos | Arm Label: Arm B: Chemotherapy + Bevacizumab + Atezolizumab; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab, Drug: Atezolizumab, Drug: Chemotherapy | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Arm A: Chemotherapy + Bevacizumab + Placebo, Arm B: Chemotherapy + Bevacizumab + Atezolizumab | Intervention Type: DRUG; Name: Atezolizumab; Assigned to Arm(s): Arm B: Chemotherapy + Bevacizumab + Atezolizumab | Intervention Type: DRUG; Name: Chemotherapy; Assigned to Arm(s): Arm A: Chemotherapy + Bevacizumab + Placebo, Arm B: Chemotherapy + Bevacizumab + Atezolizumab | Intervention Type: DRUG; Name: Placebos; Assigned to Arm(s): Arm A: Chemotherapy + Bevacizumab + Placebo
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: AZD2281 | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: matching placebo | Intervention Type: DRUG; Name: AZD2281; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: matching placebo; Assigned to Arm(s): 2
C: Arm Label: Bevacizumab + Paclitaxel + Carboplatin; Type: EXPERIMENTAL; Interventions: Drug: Paclitaxel, Drug: Bevacizumab, Drug: Carboplatin | Arm Label: Placebo + Paclitaxel + Carboplatin; Type: PLACEBO_COMPARATOR; Interventions: Drug: Paclitaxel, Drug: Carboplatin, Drug: Placebo | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Bevacizumab + Paclitaxel + Carboplatin, Placebo + Paclitaxel + Carboplatin | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Bevacizumab + Paclitaxel + Carboplatin | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Bevacizumab + Paclitaxel + Carboplatin, Placebo + Paclitaxel + Carboplatin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo + Paclitaxel + Carboplatin
D: Arm Label: Chemotherapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: liposomal doxorubicin, Drug: paclitaxel, Drug: topotecan | Arm Label: Chemotherapy + Bevacizumab; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab, Drug: liposomal doxorubicin, Drug: paclitaxel, Drug: topotecan | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Chemotherapy + Bevacizumab | Intervention Type: DRUG; Name: liposomal doxorubicin; Assigned to Arm(s): Chemotherapy, Chemotherapy + Bevacizumab | Intervention Type: DRUG; Name: paclitaxel; Assigned to Arm(s): Chemotherapy, Chemotherapy + Bevacizumab | Intervention Type: DRUG; Name: topotecan; Assigned to Arm(s): Chemotherapy, Chemotherapy + Bevacizumab

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase II Randomised, Double Blind, Multicentre Study to Assess the Efficacy of AZD2281 in the Treatment of Patients With Platinum Sensitive Relapsed Serous Ovarian Cancer Following Treatment With Two or More Platinum Containing Regimens
Brief Summary: The primary purpose of this study to determine if AZD2281 is effective and well tolerated in maintaining the improvement in your cancer after previous platinum-based chemotherapy


Options:
A: Arm Label: Cyclophosphamide and BIBF-1120; Type: EXPERIMENTAL; Interventions: Drug: BIBF 1120 | Arm Label: Cyclophosphamide and placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: BIBF 1120 | Intervention Type: DRUG; Name: BIBF 1120; Assigned to Arm(s): Cyclophosphamide and BIBF-1120, Cyclophosphamide and placebo
B: Arm Label: Arm A; Type: EXPERIMENTAL; Interventions: Drug: AMG 386, Drug: Paclitaxel | Arm Label: Arm B; Type: EXPERIMENTAL; Interventions: Drug: AMG 386, Drug: Paclitaxel | Arm Label: Arm C; Type: ACTIVE_COMPARATOR; Interventions: Drug: Paclitaxel, Drug: AMG 386 Placebo | Intervention Type: DRUG; Name: AMG 386; Assigned to Arm(s): Arm A | Intervention Type: DRUG; Name: AMG 386; Assigned to Arm(s): Arm B | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Arm A, Arm B, Arm C | Intervention Type: DRUG; Name: AMG 386 Placebo; Assigned to Arm(s): Arm C
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Paclitaxel, Drug: AMG 386 Placebo, Drug: Carboplatin | Arm Label: AMG 386; Type: ACTIVE_COMPARATOR; Interventions: Drug: AMG 386, Drug: Paclitaxel, Drug: Carboplatin | Intervention Type: DRUG; Name: AMG 386; Assigned to Arm(s): AMG 386 | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): AMG 386, Placebo | Intervention Type: DRUG; Name: AMG 386 Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): AMG 386, Placebo
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: AZD2281 | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: matching placebo | Intervention Type: DRUG; Name: AZD2281; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: matching placebo; Assigned to Arm(s): 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase II Randomised, Double Blind, Multicentre Study to Assess the Efficacy of AZD2281 in the Treatment of Patients With Platinum Sensitive Relapsed Serous Ovarian Cancer Following Treatment With Two or More Platinum Containing Regimens
Brief Summary: The primary purpose of this study to determine if AZD2281 is effective and well tolerated in maintaining the improvement in your cancer after previous platinum-based chemotherapy


Options:
A: Arm Label: Active Comparator; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carboplatin, Drug: Paclitaxel | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: AZD0530, Drug: Carboplatin, Drug: Paclitaxel | Intervention Type: DRUG; Name: AZD0530; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): 2, Active Comparator | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): 2, Active Comparator
B: Arm Label: KU-0059436; Type: EXPERIMENTAL; Interventions: Drug: KU-0059436 (AZD2281)(PARP inhibitor) | Intervention Type: DRUG; Name: KU-0059436 (AZD2281)(PARP inhibitor); Assigned to Arm(s): KU-0059436
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: AZD2281 | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: matching placebo | Intervention Type: DRUG; Name: AZD2281; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: matching placebo; Assigned to Arm(s): 2
D: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Topotecan, Drug: CCI-779 (temsirolimus) | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: Topotecan, Drug: CCI-779 (temsirolimus) | Intervention Type: DRUG; Name: Topotecan; Assigned to Arm(s): A, B | Intervention Type: DRUG; Name: CCI-779 (temsirolimus); Assigned to Arm(s): A, B

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase II Randomised, Double Blind, Multicentre Study to Assess the Efficacy of AZD2281 in the Treatment of Patients With Platinum Sensitive Relapsed Serous Ovarian Cancer Following Treatment With Two or More Platinum Containing Regimens
Brief Summary: The primary purpose of this study to determine if AZD2281 is effective and well tolerated in maintaining the improvement in your cancer after previous platinum-based chemotherapy


Options:
A: Arm Label: Olaparib tablets p.o. 300mg twice daily; Type: EXPERIMENTAL; Interventions: Drug: Olaparib 300mg tablets | Arm Label: Placebo tablets p.o. twice daily; Type: PLACEBO_COMPARATOR; Interventions: Drug: Olaparib 300mg tablets | Intervention Type: DRUG; Name: Olaparib 300mg tablets; Assigned to Arm(s): Olaparib tablets p.o. 300mg twice daily, Placebo tablets p.o. twice daily
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: AZD2281 | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: matching placebo | Intervention Type: DRUG; Name: AZD2281; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: matching placebo; Assigned to Arm(s): 2
C: Arm Label: Intraperitoneal bevacizumab+ carboplatin; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab, Drug: Carboplatin, Drug: paclitaxel | Arm Label: Intraperitoneal carboplatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carboplatin, Drug: paclitaxel | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Intraperitoneal bevacizumab+ carboplatin | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Intraperitoneal bevacizumab+ carboplatin, Intraperitoneal carboplatin | Intervention Type: DRUG; Name: paclitaxel; Assigned to Arm(s): Intraperitoneal bevacizumab+ carboplatin, Intraperitoneal carboplatin
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Pazopanib; Type: EXPERIMENTAL; Interventions: Drug: Pazopanib | Intervention Type: DRUG; Name: Pazopanib; Assigned to Arm(s): Pazopanib | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase II Randomised, Double Blind, Multicentre Study to Assess the Efficacy of AZD2281 in the Treatment of Patients With Platinum Sensitive Relapsed Serous Ovarian Cancer Following Treatment With Two or More Platinum Containing Regimens
Brief Summary: The primary purpose of this study to determine if AZD2281 is effective and well tolerated in maintaining the improvement in your cancer after previous platinum-based chemotherapy


Options:
A: Arm Label: A: Paclitaxel; Type: ACTIVE_COMPARATOR; Interventions: Drug: Paclitaxel | Arm Label: B: Olaparib; Type: EXPERIMENTAL; Interventions: Drug: Olaparib | Arm Label: C: Olaparib and Cediranib; Type: EXPERIMENTAL; Interventions: Drug: Olaparib, Drug: Cediranib | Intervention Type: DRUG; Name: Olaparib; Assigned to Arm(s): B: Olaparib, C: Olaparib and Cediranib | Intervention Type: DRUG; Name: Cediranib; Assigned to Arm(s): C: Olaparib and Cediranib | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): A: Paclitaxel
B: Arm Label: Treatment A; Type: EXPERIMENTAL; Interventions: Drug: AZD2281 | Arm Label: Treatment B; Type: EXPERIMENTAL; Interventions: Drug: AZD2281 | Arm Label: Treatment C; Type: EXPERIMENTAL; Interventions: Drug: AZD2281 | Intervention Type: DRUG; Name: AZD2281; Assigned to Arm(s): Treatment A, Treatment B, Treatment C
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: AZD2281 | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: matching placebo | Intervention Type: DRUG; Name: AZD2281; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: matching placebo; Assigned to Arm(s): 2
D: Arm Label: Part 1 (Phase 1); Type: EXPERIMENTAL; Interventions: Drug: Rucaparib | Arm Label: Part 2A (Phase 2); Type: EXPERIMENTAL; Interventions: Drug: Rucaparib | Arm Label: Part 2B (Phase 2); Type: EXPERIMENTAL; Interventions: Drug: Rucaparib | Arm Label: Part 3 (Phase 2); Type: EXPERIMENTAL; Interventions: Drug: Rucaparib | Intervention Type: DRUG; Name: Rucaparib; Assigned to Arm(s): Part 1 (Phase 1), Part 2A (Phase 2), Part 2B (Phase 2), Part 3 (Phase 2)

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Multicentre, Phase II, Parallel-Group Trial of Vandetanib Monotherapy or Vandetanib in Combination With Gemcitabine Versus Gemcitabine Plus Vandetanib Matching Placebo in Subjects With Advanced Biliary Tract Cancer (Gallbladder Cancer, Cancer of the Extrahepatic Bile Duct, Intrahepatic Cholangiocarcinoma and Ampullary Carcinoma)
Brief Summary: The primary objective of the trial is to determine the efficacy of VANDETANIB monotherapy or VANDETANIB plus GEMCITABINE or PLACEBO plus GEMCITABINE in prolonging the progression-free survival (PFS) at the trial closure in patients with advanced (unresectable or metastatic) biliary tract cancer.


Options:
A: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: ZD6474, Vandetanib | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: ZD6474, Vandetanib, Drug: Gemcitabine | Arm Label: C; Type: PLACEBO_COMPARATOR; Interventions: Drug: Gemcitabine, Drug: Placebo matching ZD6474 | Intervention Type: DRUG; Name: ZD6474, Vandetanib; Assigned to Arm(s): A | Intervention Type: DRUG; Name: ZD6474, Vandetanib; Assigned to Arm(s): B | Intervention Type: DRUG; Name: Gemcitabine; Assigned to Arm(s): B, C | Intervention Type: DRUG; Name: Placebo matching ZD6474; Assigned to Arm(s): C
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Gemox, Cetuximab | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Gemox, Cetuximab | Intervention Type: DRUG; Name: Gemox, Cetuximab; Assigned to Arm(s): 1, 2
C: Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: cisplatin, Drug: cediranib, Drug: gemcitabine | Arm Label: Arm A; Type: PLACEBO_COMPARATOR; Interventions: Drug: gemcitabine, Drug: cisplatin, Drug: Placebo | Intervention Type: DRUG; Name: gemcitabine; Assigned to Arm(s): Arm A | Intervention Type: DRUG; Name: cisplatin; Assigned to Arm(s): Arm A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Arm A | Intervention Type: DRUG; Name: cisplatin; Assigned to Arm(s): B | Intervention Type: DRUG; Name: cediranib; Assigned to Arm(s): B | Intervention Type: DRUG; Name: gemcitabine; Assigned to Arm(s): B
D: Arm Label: SP treatment; Type: EXPERIMENTAL; Interventions: Drug: S-1 plus cisplatin | Arm Label: GP treatment; Type: ACTIVE_COMPARATOR; Interventions: Drug: Gemcitabine plus Cisplatin | Intervention Type: DRUG; Name: S-1 plus cisplatin; Assigned to Arm(s): SP treatment | Intervention Type: DRUG; Name: Gemcitabine plus Cisplatin; Assigned to Arm(s): GP treatment

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Multicenter, Randomized, Double Blind, Clinical Trial to Compare the Clinical and Radiological Efficacy of Equivalent Doses of Methylprednisolone Administered Orally or Intravenously in Patients With Multiple Sclerosis During Relapse
Brief Summary: This is a phase IV, multicenter, randomized, double blind clinical trial. The investigators will study 48 patients with remitting relapsing multiple sclerosis (MS) experiencing moderate or severe attack receiving immunomodulatory therapy or not. Patients will be randomly assigned to one of the two groups.


Options:
A: Arm Label: Group 1; Type: EXPERIMENTAL; Interventions: Drug: peginterferon beta-1a, Drug: Rebif | Arm Label: Group 2; Type: EXPERIMENTAL; Interventions: Drug: peginterferon beta-1a, Drug: Rebif | Intervention Type: DRUG; Name: peginterferon beta-1a; Assigned to Arm(s): Group 1, Group 2 | Intervention Type: DRUG; Name: Rebif; Assigned to Arm(s): Group 1, Group 2
B: Arm Label: Interferon beta-1a 44 mcg SC; Type: ACTIVE_COMPARATOR; Interventions: Drug: Interferon beta-1a, Drug: Ocrelizumab-matching placebo | Arm Label: Ocrelizumab; Type: EXPERIMENTAL; Interventions: Drug: Ocrelizumab, Drug: Interferon beta-1a-matching placebo | Intervention Type: DRUG; Name: Interferon beta-1a; Assigned to Arm(s): Interferon beta-1a 44 mcg SC | Intervention Type: DRUG; Name: Ocrelizumab-matching placebo; Assigned to Arm(s): Interferon beta-1a 44 mcg SC | Intervention Type: DRUG; Name: Ocrelizumab; Assigned to Arm(s): Ocrelizumab | Intervention Type: DRUG; Name: Interferon beta-1a-matching placebo; Assigned to Arm(s): Ocrelizumab
C: Arm Label: Glatiramer acetate; Type: EXPERIMENTAL; Interventions: Drug: Glatiramer Acetate (DB), Drug: Glatiramer Acetate (OL) | Arm Label: Placebo (DB) to GA (OL); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Glatiramer Acetate (OL) | Intervention Type: DRUG; Name: Glatiramer Acetate (DB); Assigned to Arm(s): Glatiramer acetate | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo (DB) to GA (OL) | Intervention Type: DRUG; Name: Glatiramer Acetate (OL); Assigned to Arm(s): Glatiramer acetate, Placebo (DB) to GA (OL)
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: methylprednisolone, Drug: Placebo | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: methylprednisolone, Drug: Placebo | Intervention Type: DRUG; Name: methylprednisolone; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: methylprednisolone; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 1, 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: The purpose of this study is to compare the effects on visual development, growth, cognitive development, tolerance, and blood chemistry parameters in term infants fed one of four study formulas containing various levels of DHA and ARA.


Options:
A: Arm Label: Commercially available infant formula A; Type: EXPERIMENTAL; Interventions: Other: Infant Formula milk based | Arm Label: Commercially available infant formula B; Type: ACTIVE_COMPARATOR; Interventions: Other: Infant formula milk based | Intervention Type: OTHER; Name: Infant Formula milk based; Assigned to Arm(s): Commercially available infant formula A | Intervention Type: OTHER; Name: Infant formula milk based; Assigned to Arm(s): Commercially available infant formula B
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: DHA and ARA | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Other: DHA and ARA | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Other: DHA and ARA | Arm Label: 4; Type: OTHER; Interventions: Other: Control | Intervention Type: OTHER; Name: DHA and ARA; Assigned to Arm(s): 1, 2, 3 | Intervention Type: OTHER; Name: Control; Assigned to Arm(s): 4
C: Intervention Type: PROCEDURE; Name: Supplement of fatty acid (DHA and AA); Assigned to Arm(s): N/A
D: Arm Label: Fish Oil; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Fish Oil | Arm Label: Sunflower oil; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Sunflower Oil | Intervention Type: DIETARY_SUPPLEMENT; Name: Fish Oil; Assigned to Arm(s): Fish Oil | Intervention Type: DIETARY_SUPPLEMENT; Name: Sunflower Oil; Assigned to Arm(s): Sunflower oil

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: The purpose of this study is to compare the effects on visual development, growth, cognitive development, tolerance, and blood chemistry parameters in term infants fed one of four study formulas containing various levels of DHA and ARA.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: DHA and ARA | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Other: DHA and ARA | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Other: DHA and ARA | Arm Label: 4; Type: OTHER; Interventions: Other: Control | Intervention Type: OTHER; Name: DHA and ARA; Assigned to Arm(s): 1, 2, 3 | Intervention Type: OTHER; Name: Control; Assigned to Arm(s): 4
B: Arm Label: standard infant formula; Type: ACTIVE_COMPARATOR; Interventions: Other: standard infant formula | Arm Label: modified infant formula; Type: EXPERIMENTAL; Interventions: Other: modified infant formula | Arm Label: breast milk; Type: OTHER; Interventions: Other: breast milk | Intervention Type: OTHER; Name: standard infant formula; Assigned to Arm(s): standard infant formula | Intervention Type: OTHER; Name: modified infant formula; Assigned to Arm(s): modified infant formula | Intervention Type: OTHER; Name: breast milk; Assigned to Arm(s): breast milk
C: Arm Label: DHA capsules; Type: EXPERIMENTAL; Interventions: Drug: DHA | Arm Label: Placebo capsules; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo capsule | Intervention Type: DRUG; Name: DHA; Assigned to Arm(s): DHA capsules | Intervention Type: OTHER; Name: Placebo capsule; Assigned to Arm(s): Placebo capsules
D: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Docosahexaenoic acid (DHA) | Intervention Type: DIETARY_SUPPLEMENT; Name: Docosahexaenoic acid (DHA); Assigned to Arm(s): 2

Answer: A